

PRINT AVAIL ABLE COPY

Beiersdorf 569.1-HCL  
6713-Dr. Lt-sch 196-129

1. A method for the prophylaxis and treatment of rosacea and couperose which comprises applying to a patient in need thereof an effective amount of one compound or two or more compounds selected from the group consisting of NO-synthase inhibitors and salts thereof.

Please substitute claim 3 with amended claim 3:

3. Cosmetic or dermatological topical preparations comprising a NO-synthase inhibitor or salt thereof which is selected from the group consisting of L-MEA, 2-Iminobiotin, L-NIO, S-Methylisothiourea sulphate, S-Methyl-L-thiocitrulline, L-NIL, 7-Nitroindazole, PBITU, L-Thiocitrulline, alpha-N-acetyl-L-NAME and salts thereof.

Please substitute claims 9 and 10 with amended claims 9 and 10:

9. Cosmetic or dermatological topical preparations according to Claim 3, wherein said NO-synthase inhibitor or salts thereof is selected from the group consisting of 2-Iminobiotin, L-NIO, S-Methylisothiourea sulphate, S-Methyl-L-thiocitrulline, L-NIL, 7-Nitroindazole, PBITU, L-Thiocitrulline, and salts thereof.

10. Preparation according to Claim 9, wherein said NO-synthase inhibitor or salts thereof further comprises L-NAME.

Please cancel claims 16.

Please add new claims 19-27:

19. A method for the prophylaxis and treatment of rosacea and couperose which comprises applying to a patient in need thereof an effective amount of an NO-synthase inhibitor or salt thereof which is selected from the group consisting of L-MEA, 2-Iminobiotin, L-NIO, S-Methylisothiourea sulphate, S-Methyl-L-thiocitrulline, L-NIL, 7-Nitroindazole, PBITU, L-Thiocitrulline, alpha-N-acetyl-L-NAME and salts thereof.

20. The method of claim 19, wherein said NO-synthase inhibitor is selected from the group consisting of 2-Iminobiotin, L-NIO, S-Methylisothiourea sulphate, S-Methyl-L-thiocitrulline, L-NIL, 7-Nitroindazole, PBITU, L-Thiocitrulline and salts thereof.

21. The method of claim 20, wherein said NO-synthase inhibitor or salt thereof further comprises L-NAME.

**BEST AVAILABLE COPY**

Beiersdorf 569.1-HCL  
6713-Dr. Lt-sch 196-129

*Initials*

*CCW/DP*

*b6 b7c*

22. The method of claim 20 or 21, wherein the amount of NO-synthase inhibitor is from 0.001% to 20% by weight based on the total weight of the preparation.
23. The method of claim 22, wherein the amount of NO-synthase inhibitor is from 0.01% to 10% by weight based on the total weight of the preparation.
24. The method of claim 23, wherein the amount of NO-synthase inhibitor is from 0.1 to 5% by weight based on the total weight of the preparation.
25. The preparation of claim 9 or 10, wherein the amount of NO-synthase inhibitor is from 0.001% to 20% by weight based on the total weight of the preparation.
26. The preparation of claim 25, wherein the amount of NO-synthase inhibitor is from 0.001% to 20% by weight based on the total weight of the preparation.
27. The preparation of claim 26, wherein the amount of NO-synthase inhibitor is from 0.001% to 20% by weight based on the total weight of the preparation.

**CONDITIONAL PETITION FOR EXTENSION OF TIME**

If entry and consideration of the amendments above requires an extension of time, Applicants respectfully request that this be considered a petition therefore. The Assistant Commissioner is authorized to charge any fee(s) due in this connection to Deposit Account No. 14-1263.

**ADDITIONAL FEE**

Please charge any insufficiency of fees, or credit any excess, to Deposit Account No. 14-1263.

**REMARKS**

**Summary of Claim Amendments**

Claim 1 has been amended to better place the claim language in conformance with U.S. practice. Claims 3, 9 have been amended to encompass the Examples 12-19 in the specification; claim 10, examples 10 and 11. New claims 19-21 are the corresponding method of use claims for amended claims 3, 9 and 10. New claims 22-27 incorporate % weight limitations in the respective claims (support can be found in the